Spruce Street Capital LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Spruce Street Capital LP disclosed 30 US equity positions worth $509.7m in its Q2 2026 13F filing. The largest position was KINIKSA PHARMACEUTICALS INTL at 11.5% of the reported book, followed by RLAY and LB PHARMACEUTICALS INC. Against the Q1 2026 filing, it opened 5 new positions, added to 8 and reduced 1 among the top 30 holdings.
What did Spruce Street Capital LP own in Q2 2026? Top 30 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | KINIKSA PHARMACEUTICALS INTL | 11.5% | $58.7m | 918,070 | 21% | added | |
| 2 | RLAY RELAY THERAPEUTICS INC | Healthcare | 11.0% | $55.8m | 2,984,125 | 0% | held |
| 3 | LB PHARMACEUTICALS INC | 8.8% | $44.7m | 1,376,159 | 0% | held | |
| 4 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 8.7% | $44.2m | 6,391,328 | 2% | added |
| 5 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 7.0% | $35.7m | 1,353,047 | 2% | added |
| 6 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 6.8% | $34.6m | 354,816 | -5% | reduced |
| 7 | ALKS ALKERMES PLC | Healthcare | 5.6% | $28.5m | 543,876 | 71% | added |
| 8 | SVRA SAVARA INC | Healthcare | 4.2% | $21.3m | 3,452,576 | 2% | added |
| 9 | PCVX VAXCYTE INC | Healthcare | 3.5% | $17.8m | 306,047 | 25% | added |
| 10 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 3.3% | $16.7m | 329,006 | 0% | held |
| 11 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 3.1% | $15.9m | 1,088,731 | 17% | added |
| 12 | CATX PERSPECTIVE THERAPEUTICS INC | 2.5% | $12.6m | 3,693,931 | 41% | added | |
| 13 | INFLARX NV | 2.4% | $12.0m | 5,352,198 | – | new | |
| 14 | SRZN SURROZEN INC | 2.2% | $11.2m | 432,040 | 0% | held | |
| 15 | ALMS ALUMIS INC | Healthcare | 2.2% | $11.0m | 392,574 | 0% | held |
| 16 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 2.0% | $9.9m | 4,059,054 | 0% | held |
| 17 | NERV MINERVA NEUROSCIENCES INC | 1.8% | $9.2m | 1,655,500 | 0% | held | |
| 18 | SABS SAB BIOTHERAPEUTICS INC | 1.7% | $8.6m | 2,198,502 | 0% | held | |
| 19 | ANTX AN2 THERAPEUTICS INC | 1.6% | $8.0m | 1,661,073 | 0% | held | |
| 20 | ERAS ERASCA INC | Healthcare | 1.5% | $7.7m | 422,543 | 0% | held |
| 21 | IKT INHIBIKASE THERAPEUTICS INC | 1.4% | $7.3m | 3,581,603 | 0% | held | |
| 22 | RESEARCH ALLIANCE CORP III | 1.0% | $5.3m | 500,000 | – | new | |
| 23 | HELIX ACQUISITION CORP III | 1.0% | $5.3m | 500,000 | 0% | held | |
| 24 | ZLAB ZAI LAB LTD | Healthcare | 1.0% | $5.3m | 279,110 | – | new |
| 25 | ACHV ACHIEVE LIFE SCIENCE INC | 0.9% | $4.8m | 736,637 | – | new | |
| 26 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.8% | $4.3m | 928,593 | 0% | held |
| 27 | ALEC ALECTOR INC | Healthcare | 0.8% | $4.2m | 2,101,068 | 0% | held |
| 28 | LONA LEONABIO INC | 0.7% | $3.6m | 393,701 | 0% | held | |
| 29 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 0.7% | $3.5m | 231,585 | 0% | held |
| 30 | JATT II ACQUISITION CORP | 0.4% | $1.8m | 160,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.